Abstract
Pharmacologic agents for CNS disorders are often inhibitors that occupy receptors, with frequent unavoidable side effects likely due to continuous binding. This review summarizes development of a novel aldehyde dehydrogenase 2 (ALDH2) inhibitor that specifically targets unique drug related episodic surges in dopamine (DA), a pathophysiologic mechanism that appears to underlie much of drug-seeking behavior. We have synthesized highly selective novel ALDH2 inhibitors (ALDH2i) that block alcohol- and cocaine cue-induced surges in nucleus accumbens (NAc) DA and prevent reinstatement of alcohol heavy drinking, cocaine self-administration and reinstatement of cocaine relapse-like behavior. The mechanism of action of ALDH2i depends on inhibiting dopamine aldehyde (DOPAL) clearance by ALDH2, enabling unmetabolized DOPAL to condense with DA to generate tetrahydropapaveroline (THP). THP selectively inhibits the activated (phosphorylated) tyrosine hydroxylase (TH) to suppress DA synthesis. Selective inhibition of ALDH2 appears to have therapeutic potential for treating cue-induced drug relapse, a major unmet need for treating addicted subjects.
Keywords: Addiction, alcohol, ALDH2, cocaine, craving, relapse.
CNS & Neurological Disorders - Drug Targets
Title:From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction
Volume: 14 Issue: 6
Author(s): Ivan Diamond and Lina Yao
Affiliation:
Keywords: Addiction, alcohol, ALDH2, cocaine, craving, relapse.
Abstract: Pharmacologic agents for CNS disorders are often inhibitors that occupy receptors, with frequent unavoidable side effects likely due to continuous binding. This review summarizes development of a novel aldehyde dehydrogenase 2 (ALDH2) inhibitor that specifically targets unique drug related episodic surges in dopamine (DA), a pathophysiologic mechanism that appears to underlie much of drug-seeking behavior. We have synthesized highly selective novel ALDH2 inhibitors (ALDH2i) that block alcohol- and cocaine cue-induced surges in nucleus accumbens (NAc) DA and prevent reinstatement of alcohol heavy drinking, cocaine self-administration and reinstatement of cocaine relapse-like behavior. The mechanism of action of ALDH2i depends on inhibiting dopamine aldehyde (DOPAL) clearance by ALDH2, enabling unmetabolized DOPAL to condense with DA to generate tetrahydropapaveroline (THP). THP selectively inhibits the activated (phosphorylated) tyrosine hydroxylase (TH) to suppress DA synthesis. Selective inhibition of ALDH2 appears to have therapeutic potential for treating cue-induced drug relapse, a major unmet need for treating addicted subjects.
Export Options
About this article
Cite this article as:
Diamond Ivan and Yao Lina, From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150529144329
DOI https://dx.doi.org/10.2174/1871527314666150529144329 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology The Therapeutic Potential of Neural Stem Cells in Cerebral Ischemia
Current Signal Transduction Therapy Research Trend of Persian Medicine Based on the PubMed Database, 2015 -2019
Current Traditional Medicine A Blood Vessel Deformation Model Based Virtual-reality Simulator for the Robotic Catheter Operating System
Neuroscience and Biomedical Engineering (Discontinued) Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Evaluation of Time-Dependent Cytochrome P450 Inhibition in a High-Throughput, Automated Assay: Introducing a Novel Area Under the Curve Shift Approach
Drug Metabolism Letters History Repeats Itself: Pharmacodynamic Trends in the Treatment of Anxiety Disorders
Current Pharmaceutical Design Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action
Current Drug Targets Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease
Current Medicinal Chemistry Interactions Between Nanosized Materials and the Brain
Current Medicinal Chemistry The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets Nanocargos: A Burgeoning Quest in Cancer Management
Current Nanomedicine Pharmacogenomics of Arylamine N-acetyltransferase
Current Pharmacogenomics An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry Hallmarks in the Therapeutic Approach of Aortic Aneurysms: The Main Contributors
Current Pharmaceutical Design Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies Jatrorrhizine Protects Against Okadaic Acid Induced Oxidative Toxicity Through Inhibiting the Mitogen-Activated Protein Kinases Pathways in HT22 Hippocampal Neurons
CNS & Neurological Disorders - Drug Targets